Product Description

CJC-1295 with DAC

Product Overview

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic, long-acting analogue of growth hormone-releasing hormone (GHRH). It has been designed to bind to albumin in the bloodstream, extending its persistence in circulation compared with naturally occurring GHRH. This modification allows researchers to investigate prolonged stimulation of the growth hormone (GH) signaling pathway.

CJC-1295 with DAC has been examined in early-stage human studies investigating its pharmacokinetic properties and effects on circulating growth hormone and insulin-like growth factor 1 (IGF-1). Published research in healthy adults demonstrated sustained increases in these hormone levels following administration. However, these studies primarily assessed hormonal and pharmacological outcomes rather than demonstrating improvements in health, physical performance, or body composition.

The compound is of scientific interest in endocrine research examining GHRH receptor signaling, pituitary hormone regulation, albumin-binding modifications, and the relationship between growth hormone and IGF-1 activity. Long-term safety and clinical efficacy remain insufficiently characterized, and CJC-1295 with DAC is not an FDA-approved therapeutic drug.

Key Research Areas

Growth hormone-releasing hormone receptor signaling and pituitary regulation

Growth hormone and IGF-1 secretion in endocrine research models

Albumin binding and prolonged peptide pharmacokinetics

Hormonal feedback mechanisms and endocrine regulation

Structure–activity relationships in modified GHRH analogues

Peptide stability, molecular characterization, and analytical verification

Handling & Reconstitution

For laboratory use, reconstitute with Bacteriostatic Water (BAC) or sterile saline. After reconstitution, the solution should be stored at 2–8°C (36–46°F) and used within the appropriate experimental window to maintain peptide stability.